AbbVie Contract Manufacturing AbbVie Contract Manufacturing

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Hackensack Meridian Health","sponsor":"Compass Pathways","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Compass Pathways Enters Into Research Collaboration Agreement with Hackensack Meridian Health to Develop Optimal Clinical Model for Investigational COMP360 Psilocybin Treatment, if FDA-Approved","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2024","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III"}]

    Find Clinical Drug Pipeline Developments & Deals by Hackensack Meridian Health

    Menu

    Hackensack Meridian Health

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Hackensack Meridian Health

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Compass Pathways Enters Into Research Collaboration Agreement with Hackensack Meridian Health to Develop Optimal Clinical Model for Investigational COMP360 Psilocybin Treat...

              Details:

              The collaboration aims to inform the delivery model design of investigational COMP360, a proprietary formulation of synthetic psilocybin, for treatment-resistant depression (TRD).

              Lead Product(s): Psilocybine

              Therapeutic Area: Psychiatry/Psychology Product Name: COMP360

              Highest Development Status: Phase III Product Type: Small molecule

              Recipient: Compass Pathways

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration January 16, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Biopharma Group offers CDMO services with expertise in contract R&D for dried products & liquid formulations.
              Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.
              Post Enquiry
              POST ENQUIRY